glp 1 pills lilly FDA approves new weight-loss pill, Foundayo Lilly launches GLP-1 pill, kicking

FDA Warns Novo Nordisk on Unreported Deaths CEO & Founder at LlamaLab FDA Cites 'Systemic Failures' in Novo Nordisk's Reporting of Ozempic Deaths The FDA issued a warning letter to Novo Nordisk on March 5, 2026, citing "systemic failures" in the company's adverse event reporting for its semaglutide and liraglutide drugs including at least two unreported patient deaths and a suicide case that had still not been submitted to the FDA as of the letter's date

Aging Pathobiology and Therapeutics , 2(1), 5861

While these drugs have been life-changing for many, there is a growing interest in finding natural ways to boost GLP-1 production without relying solely on medication

The Kaplan-Meier-based cumulative event probability is presented in Figure 2 for time to first occurrence of the primary MACE composite endpoint by treatment arm